20190710 PR MHRA TG4050 EN
Category: Myvac
Transgene receives FDA IND Clearance for Lead myvac® Individualized Immunotherapy, TG4050, to Commence Clinical Development in Ovarian Cancer
20190513 PR IND TG4050 EN
Transgene to start clinical development of lead myvac® individualized immunotherapy, TG4050, in 2019, under its partnership with NEC
20190305-PR-NEC-Agreement-US-1
myvac™ Viral based vaccine for personalized neoantigen-directed cancer therapy
Christian Ottensmeier, et al. SITC 2018, November 2018 – Abstract available on the SITC website Download the poster here Poster Presentation Collaboration between Transgene – University of Southampton, United Kingdom – La Jolla Institute for allergy and immunology, USA – University of Copenhagen, Denmark
Transgene Highlights its Broad Viral Vector Expertise at the Society for Immunotherapy of Cancer (SITC) 2018 Conference
20181107 SITC Poster EN
NEC and Transgene announce a collaboration in the field of individualized cancer immunotherapy, leveraging NEC’s AI and Transgene’s myvac™ platform
Press Release NEC- Transgene EN
Transgene to Present its Viral Vector Expertise at the Society for Immunotherapy of Cancer Conference
20181001 SITC Poster VEN
Transgene unveils myvac™, an individualized immunotherapy against solid tumors
20180924 MyVac EN
Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
K. Bendjama, E. Quéméneur Human Vaccines and Immunotherapeutics, August 2017 – Read the article Publication
